Positive impactCompany
Divi's Labs Shares In Focus: Citi Reaffirms 'Buy' With Rs 11,700 Target On Oral Wegovy Upside
NDTV Profit 2 hrs ago·23 Sept 2026, 10:14 am
Divi's Laboratories has become a focal point for investors following a bullish note from Citi. The global brokerage firm reiterated a 'Buy' rating on the stock, maintaining a price target of Rs 11,700. This move comes as the brokerage highlights the company's integrated and cost-efficient platform for manufacturing peptide-based therapies, which it believes positions Divi's well to capture future growth in this segment.
For investors, this development signals confidence in Divi's operational capabilities and its ability to benefit from the rising demand for peptide-based drugs. The stock is currently under the scanner as the market reacts to the brokerage's assessment of the company's manufacturing strengths and its potential to expand its market share in the oral Wegovy segment.
Investors should monitor upcoming clinical trial results and regulatory approvals related to peptide therapies. Keeping an eye on the company's quarterly earnings and its ability to scale production will also be crucial to understanding the long-term impact of this positive sentiment.
Key takeaways
- Category: Company.
- AI reads the tone as positive (potentially bullish) for the stock.
- Assessed as a significant, market-relevant update.
Why it matters
A meaningful update worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
